Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13115502 | 0.78 | ALDH1A1 (0.36) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13115512 | 0.73 | LMNA (0.36) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13115529 | 0.72 | HTR7 (0.38) | HPGDLMNA | |
| SCHEMBL13115511 | 0.69 | SLC22A16 (0.32) | — | |
| SCHEMBL13115500 | 0.67 | SLC22A16 (0.31) | — | |
| SCHEMBL13115525 | 0.67 | TP53 (0.44) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13115527 | 0.67 | CTSD (0.42) | HPGDLMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL8224635 | 0.62 | KMT2A (0.44) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL5995794 | 0.62 | HPGD (0.38) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL11210247 | 0.60 | MEN1 (0.50) | HPGDMEN1LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466238-B2 | Latent curing agents, epoxy resin compositions containing the same, sealing materials, and organic EL displays | MITSUI CHEMICALS, INC. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20100253213-A1 | LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONTAINING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS | MITSUI CHEMICALS, INC (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100253213-A1 | LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONTAINING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS | MITSUI CHEMICALS, INC (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100253213-A1 | LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONTAINING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS | LTA4H, EPHX2, EPHX1 | HPGD 267/4885MEN1 3875/4885LMNA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.